Yanan Cao

Yanan Cao

Auto-generated profile, based on publicly available information

Yanan Cao

Ruijin Yangtze River Delta Health Institute, Wuxi Branch of Ruijin Hospital, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2020 in Cell Discovery
Verified
Journal Article
Open access
PDF file
YCYanan Cao
Yanan Cao
LLLin Li
Lin Li
ZFZhimin Feng
Zhimin Feng
SWShengqing Wan
Shengqing Wan
PHPeide Huang
Peide Huang
WWWeiqing Wang
Weiqing Wang

30 April 2020 in Cell Research
Verified
Journal Article
Open access
PDF file
TCThe ChinaMAP Consortium
The ChinaMAP Consortium
YCYanan Cao
Yanan Cao
LLLin Li
Lin Li
Min XuMin Xu
Min Xu
ZFZhimin Feng
Zhimin Feng
WWWeiqing Wang
Weiqing Wang
Metabolic diseases are the most common and rapidly growing health issues worldwide. The massive population-based human genetics is crucial for the precise prevention and intervention of metabolic disorders. The China Metabolic Analytics Project (ChinaMAP) is based on cohort studies across diverse regions and ethnic groups with metabolic phenotypic data in China. Here, we describe the centralized analysis of the deep whole genome sequencing data and the genetic bases of metabolic traits in 10,588 individuals from the ChinaMAP. The frequency spectrum of variants, population structure, pathogenic variants and novel genomic characteristics were analyzed. The individual genetic evaluations of Mendelian diseases, nutrition and drug metabolism, and traits of blood glucose and BMI were integrated. Our study establishes a large-scale and deep resource for the genetics of East Asians and provides opportunities for novel genetic discoveries of metabolic characteristics and disorders.

23 May 2014 in Science
Verified
Journal Article
Closed access
PDF file
YCYanan Cao
Yanan Cao
MHMinghui He
Minghui He
ZGZhibo Gao
Zhibo Gao
YPYing Peng
Ying Peng
YLYanli Li
Yanli Li
GNGuang Ning
Guang Ning
Adrenal Cushing’s syndrome is caused by excess production of glucocorticoid from adrenocortical tumors and hyperplasias, which leads to metabolic disorders. We performed whole-exome sequencing of 49 blood-tumor pairs and RNA sequencing of 44 tumors from cortisol-producing adrenocortical adenomas (ACAs), adrenocorticotropic hormone–independent macronodular adrenocortical hyperplasias (AIMAHs), and adrenocortical oncocytomas (ADOs). We identified a hotspot in the PRKACA gene with a L205R mutation in 69.2% (27 out of 39) of ACAs and validated in 65.5% of a total of 87 ACAs. Our data revealed that the activating L205R mutation, which locates in the P+1 loop of the protein kinase A (PKA) catalytic subunit, promoted PKA substrate phosphorylation and target gene expression. Moreover, we discovered the recurrently mutated gene DOT1L in AIMAHs and CLASP2 in ADOs. Collectively, these data highlight potentially functional mutated genes in adrenal Cushing’s syndrome.

10 December 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYanan Cao
Yanan Cao
ZGZhibo Gao
Zhibo Gao
LLLin Li
Lin Li
XJXiuli Jiang
Xiuli Jiang
ASAijing Shan
Aijing Shan
GNGuang Ning
Guang Ning
Functional pancreatic neuroendocrine tumours (PNETs) are mainly represented by insulinoma, which secrete insulin independent of glucose and cause hypoglycaemia. The major genetic alterations in sporadic insulinomas are still unknown. Here we identify recurrent somatic T372R mutations in YY1 by whole exome sequencing of 10 sporadic insulinomas. Further screening in 103 additional insulinomas reveals this hotspot mutation in 30% (34/113) of all tumours. T372R mutation alters the expression of YY1 target genes in insulinomas. Clinically, the T372R mutation is associated with the later onset of tumours. Genotyping of YY1, a target of mTOR inhibitors, may contribute to medical treatment of insulinomas. Our findings highlight the importance of YY1 in pancreatic β-cells and may provide therapeutic targets for PNETs.

1 March 2015 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
RWRui Wang
Rui Wang
JHJie Hong
Jie Hong
YCYanan Cao
Yanan Cao
JSJuan Shi
Juan Shi
WGWeiqiong Gu
Weiqiong Gu
WWWeiqing Wang
Weiqing Wang
Objective: MicroRNAs (miRNAs) are involved in the regulation of adiposity, but functional studies have yielded inconclusive results. Examining the associations of circulating miRNAs levels with obesity and insulin sensitivity in humans may lead to improved insights.Design and methods: Serum samples collected from 112 obese and control subjects (50.0% men) were randomly divided and combined into four pools (28 samples in each obese or control pool). The genome-wide circulating miRNA profiles were detected via microarray. Elevated miR-122 was selected and validated in individual serum samples from 123 obese (46.7% men) and 107 control (50.0% men) young adults. Associations between circulating miR-122 levels and parameters related to adiposity, insulin resistance, lipid profiles and hepatic enzymes were further assessed.Results: Thirty-four miRNAs were found to be expressed differently in the sera of obese patients compared with control subjects (P<0.001). Further analyses confirmed that obese patients had 3.07-fold higher circulating miR-122 levels than controls (P<0.001). Serum miR-122 levels were correlated with BMI (r=0.469), alanine aminotransferase (r=0.634), triglycerides (r=0.448), HDL-cholesterol (r=−0.351) and homeostasis model assessment of insulin resistance (r=0.401, allP<0.01). After controlling for confounding factors, miR-122 remained as an independent risk factor for insulin resistance (OR=3.379, 95% CI=1.141–10.007,P=0.028).Conclusions: Elevated circulating miR-122 is positively associated with obesity and insulin resistance in young adults. These findings provide a better understanding regarding the role of miRNAs in adiposity and insulin sensitivity.

1 October 2009 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
YCYanan Cao
Yanan Cao
RLRuixin Liu
Ruixin Liu
XJXiuli Jiang
Xiuli Jiang
JLJieli Lu
Jieli Lu
JJJingjing Jiang
Jingjing Jiang
GNGuang Ning
Guang Ning
Menin, which is encoded by the multiple endocrine neoplasia type 1 (MEN1) gene, is a tumor suppressor and transcriptional regulator. Menin controls proliferation and apoptosis of cells, especially pancreatic β cells. We have found that menin contains two functional nuclear export signals and that there is nuclear accumulation of β-catenin in Men1-null mouse embryonic fibroblasts and insulinoma tissues from β-cell-specific Men1 knockout mice. It is reported that the deregulation of Wnt/β-catenin signaling caused by inactivation of tumor suppressors results in abnormal development or tumorigenesis. We further revealed that overexpression of menin reduces β-catenin nuclear accumulation and its transcriptional activity. Menin is able to directly interact with β-catenin and carry β-catenin out of the nucleus via nuclear-cytoplasmic shuttling in a CRM1-dependent manner. These results imply that menin may control cell proliferation through suppression of Wnt/β-catenin signaling.